- DMC Biotechnologies raised $18 million to commercialize its KeyPura precision-fermented inositol ingredients.
- Financing will support customer adoption, portfolio development and wider sales across health, wellness and personal care markets.
DMC Biotechnologies, a Morrisville, North Carolina-based health ingredient company, said Oct. 26 that it secured $18 million in financing to expand its precision-fermented KeyPura portfolio. Inceptional Partners and Sofinnova Partners co-led the round, with First Bight Ventures and existing investors Cibus Capital and Capricorn Partners also participating.
The company’s commercial lineup includes myo-inositol and D-chiro-inositol for reproductive health, metabolic wellness, infant nutrition and other specialty nutrition formulations. DMC says it produces both through precision fermentation using purified, food-grade dextrose, providing a controlled production route designed for consistent specifications and scalable output.
The financing will support customer adoption, distribution relationships and development of additional health and wellness ingredients. DMC has not disclosed how the capital will be split or identified its next bioactives. The company’s April agreement with LBB Specialties already provides distribution for the two KeyPura ingredients in the United States and Canada across human nutrition, food, personal care and life science markets.
DMC also helped establish Biotech Open Platform, a fermentation and purification scale-up center opened in France in September. That separate platform includes a fermentation line of up to 15,000 liters, while the new financing announcement focuses on DMC’s own ingredient commercialization rather than a new facility or disclosed capacity addition.
“We’ve demonstrated our ability to develop and produce high-quality ingredients through precision fermentation.”
Jim Flatt, CEO of DMC Biotechnologies
